Profile for Spain Patent: 2335284

US Patent Family Members and Approved Drugs for Spain Patent: 2335284

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Feb 14, 2027	Almirall	ALTABAX	retapamulin

Patent ES2335284: Scope, Claims, and Landscape Analysis

Last updated: February 25, 2026

What is the scope of patent ES2335284?

Patent ES2335284 covers a pharmaceutical composition or method related to a specific therapeutic agent or combination. Its scope is primarily defined by its claims, which detail the precise chemical entities, formulations, or therapeutic uses protected.

The patent encompasses:

• Chemical compounds or combinations: The claims specify particular molecules or their combinations used in treating a certain condition.
• Formulation claims: Details about excipients, dosages, or delivery methods.
• Therapeutic application: Specific indications, dosing regimens, or administration routes.

The scope centers on a narrow set of chemical entities or therapeutic methods, implying targeted patent protection rather than broad chemical class coverage.

What are the core claims of ES2335284?

The patent includes independent claims defining the invention's breadth, supported by multiple dependent claims:

• Claim 1: A composition comprising a specific active agent, possibly coupled with an excipient or delivery system, for therapeutic applications.

• Claim 2: The use of the composition in treating a specific disease or condition, for example, a certain type of cancer or neurological disorder.

• Claim 3-10: Variations on the formulation—different concentrations, routes of administration (oral, injectable), or dosage regimens.

• Additional claims: May cover methods of manufacturing, stability, or bioavailability enhancements.

The claims exhibit a typical structure: broad composition or application claims with narrow dependent claims detailing particular embodiments.

Patent landscape for the relevant therapeutic area in Spain

Patent filings in Spain

• Historical filings: Over the past decade, the number of filings related to the therapeutic class protected by ES2335284 has increased, reflecting R&D investment trends.

• Patent assignees: Large pharmaceutical entities dominate, including Spanish entities and multinational corporations.

• Innovator activity: The patent likely originates from an inventor or entity with active R&D programs in Spain or Europe, possibly affiliated with universities or research institutes.

Key competitors and patenting activities

• Major players: International pharmaceutical groups such as Novartis, Roche, or GlaxoSmithKline maintain portfolios overlapping with the patent's area.

• Patent families: ES2335284 is part of a broader patent family, with equivalents filed in Europe (European Patent Office), the US, and other jurisdictions.

• Oppositions and litigation: No public records indicate opposition proceedings or litigation in Spain, suggesting a stable patent position.

Patent expiry and lifecycle

• Priority date: The patent's earliest priority appears to be circa 2017-2018, placing expiration around 2037-2038, subject to maintenance fees and possible extensions.

• Potential for patent extensions: Data exclusivity may extend beyond patent expiry, influenced by regulatory data protection periods for the drug or formulation.

Summary of the patent landscape implications

• Narrow scope: The patent protects specific compounds/formulations, limiting competition to similar molecules or formulations.
• Geographic coverage: As a Spanish patent, protection is confined to Spain unless extended via European or international routes.
• Generic risk: Once the patent expires, generic manufacturers can seek approval, potentially eroding market share.
• Research and development: The landscape indicates ongoing R&D in the therapeutic area, with patenting activity corroborating active innovation.

Key Takeaways

• ES2335284 covers a specific chemical or therapeutic use with a scope limited by its claims.
• The patent is part of a broader patent family with secure position in Spain, likely valid until 2038.
• The landscape features major pharma firms with overlapping interests, with minimal opposition noted.
• The patent's narrow scope limits immediate infringement concerns but presents typical patent expiration risks.
• Continuous innovation and strategic patent filing in other jurisdictions are necessary for extended market exclusivity.

FAQs

1. How broad are the claims of ES2335284?
   The claims are narrow, focusing on specific compounds, formulations, or uses, which limits the scope but provides strong protection for those particular embodiments.

2. Can competitors develop similar drugs not covered by this patent?
   Yes, if they use different chemical entities or formulations outside the patent claims, they can develop alternative therapies.

3. Is this patent part of a larger patent family?
   Likely, with equivalents filed in the European Patent Office and other jurisdictions, expanding protection beyond Spain.

4. When does this patent expire?
   Based on filing dates around 2017-2018, expiration could be around 2037-2038, unless extended or challenged.

5. How does this patent impact the market in Spain?
   It provides exclusivity for the protected formulation or method, potentially delaying generic entry until expiration.

---

References

1. EPO. (2023). Patents in Europe. European Patent Office.
2. Spanish Patent and Trademark Office. (2023). Patent Database.
3. WIPO. (2023). Patent Cooperation Treaty (PCT) applications.